Survodutide vs 5-Amino-1MQ
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: BI 456906
A dual GLP-1/glucagon receptor agonist in development for obesity and MASH. Has FDA Breakthrough Therapy Designation for MASH with fibrosis.
Also: 5-amino-1-methylquinolinium, NNMT Inhibitor
A selective NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular energy metabolism. Not a peptide but a small molecule research compound commonly used alongside peptides for fat loss and metabolic support.
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Survodutide has stronger research evidence (Human Trials) compared to 5-Amino-1MQ (Animal Studies).
Detailed Comparison
| Attribute | Survodutide | 5-Amino-1MQ |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Survodutide activates both GLP-1 receptors (appetite suppression, glucose control) and glucagon receptors (increased energy expenditure, reduced liver fat). The glucagon component adds metabolic benefits beyond pure GLP-1 agonists. | 5-Amino-1MQ inhibits NNMT, an enzyme that regulates NAD+ and SAM (S-adenosyl methionine) levels. By blocking NNMT, it increases NAD+ availability, enhancing mitochondrial function, promoting fat oxidation, and supporting cellular energy metabolism. It does not affect appetite or food intake. |
| Common Dosing | Limited community data available See research protocols | 50-75 mg daily Once daily, morning |
| Administration | Subcutaneous injection weekly | Subcutaneous injection or oral |
| Typical Duration | Long-term use expected | 4-6 weeks (cycling recommended) |
| Best Time to Take | Before bed or morning (fasted) | Morning, fasted |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Phase 2 showed 83% of patients had MASH resolution vs 18% placebo. Phase 3 SYNCHRONIZE trials for obesity expected to complete early 2026. LIVERAGE trials for MASH enrolling 3,000+ participants. | Mouse studies showed over 30% decrease in adipocyte size and 40% decrease in adipocyte volume. Treated mice had 30% lower total cholesterol. No significant impact on food intake or adverse effects observed. Human clinical data remains limited. |
Frequently Asked Questions: Survodutide vs 5-Amino-1MQ
What is the difference between Survodutide and 5-Amino-1MQ?
Survodutide is a weight loss peptide that a dual glp-1/glucagon receptor agonist in development for obesity and mash. has fda breakthrough therapy designation for mash with fibrosis. 5-Amino-1MQ is a weight loss peptide that a selective nnmt (nicotinamide n-methyltransferase) inhibitor that enhances cellular energy metabolism. not a peptide but a small molecule research compound commonly used alongside peptides for fat loss and metabolic support. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Survodutide or 5-Amino-1MQ?
Neither is universally "better" - the choice depends on your specific goals. Survodutide is typically used for weight loss purposes, while 5-Amino-1MQ is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Survodutide and 5-Amino-1MQ be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Survodutide and 5-Amino-1MQ together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Survodutide and 5-Amino-1MQ is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.